---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-089299"
form_type: "8-K"
ticker: "TELA"
cik: "0001561921"
company_name: "TELA Bio, Inc."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T22:05:50.018016+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# TELA Bio Q2 2023 revenue $14.5M (+39% YoY); reaffirms FY23 guidance $60-65M

## Summary
- Q2 revenue $14.5M, up 39% YoY; H1 revenue $26.4M, up 42% YoY.
- Gross margin improved to 70% vs 63% in Q2 2022 due to better inventory management.
- Net loss $10.8M, narrower than $12.7M loss in prior-year quarter.
- FY2023 revenue guidance reaffirmed: $60-65M, representing 45-57% growth.
- Cash $65.3M after underwritten public offering netting ~$46.4M.

## SEC filing metadata
- accession: 0001104659-23-089299
- form_type: 8-K
- ticker: TELA
- cik: 0001561921
- company_name: TELA Bio, Inc.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1561921/000110465923089299/0001104659-23-089299-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1561921/000110465923089299/tm2323228d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-089299
- JSON: https://secwatch.observer/filing/0001104659-23-089299.json
- Plain text: https://secwatch.observer/filing/0001104659-23-089299.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.